Cytokinetics, Inc. (CYTK) Posts Q1 Loss of 27c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Cytokinetics' (CYTK) Q1 Results Solid, BENEFIT Remains in Focus - Roth
May 7, 2014 9:29 AM EDTRoth Capital has Cytokinetics (Nasdaq: CYTK) at Buy with a target price of $13 following Q1 results.
After markets closed Tuesday, Cytokinetics reported Q1 EPS of ($0.27), $0.07 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $8 million versus the consensus estimate of $7.69 million.
Analyst Joseph Pnatginis noted that Cytokinetics is now prepping for the potential next steps for tirasemtiv... More
Cytokinetics (CYTK) a Buy on Partnered Pipeline, Needham & Company Says
May 7, 2014 8:41 AM EDTNeedham & Company analyst Chad Messer reiterated a Buy rating and $15 price target on Cytokinetics (NASDAQ: CYTK) following Q1 results.
Messer comments, "Cytokinetics ended 1Q:14 with $101.9 million in cash, which we estimate is sufficient to fund the company at least through 2015. On its earnings... More
